In AA, greater vs lesser preoperative tumor burden was associated with increased median serum TM levels (CEA: 9.5 [IQR, 3.7-42.3] ng/mL vs 3.0 [IQR, 2.1-5.9] ng/mL; CA19-9: 31.1 [IQR, 10.0-102.3] U/mL vs 15.0 [IQR, 6.1-25.5] U/mL; CA125: 28.7 [IQR, 13.9-58.5] U/mL vs 11.5 [IQR, 8.0-17.3] U/mL; all P < .001), and after CRS vs before, percentages of patients with TM elevation were significantly lower (CEA: 77 of 223 [34.5%] vs 222 of 340 [65.3%]; CA19-9: 45 of 194 [23.2%] vs 117 of 324 [36.1%]; CA125: 13 of 203 [6.4%] vs 98 of 325 [30.2%]; all P < .001). The gene discussed is CEACAM5; the disease is neoplasm.